[1] Winnard P Jr, Chang F, Rusekowski M, et al. Preparation and use of NHS-MAG3 for technetium-99m labeling of DNA[J]. Nucl Med Biol, 1997, 24(5):425-432.
[2] 齐传民,郭雪峰,张华北,等.新N3S型类肽配体的合成及其小鼠体内的生物分布研究[J].药学学报,2002,37(6):428-432.
[3] 高再荣,张凯军,张永学.Survivin反义寡核苷酸的99mTc标记及在肝癌细胞中的表达[J].放射学实践,2004,19(1):50-52.
[4] Hnatowich DJ, Qu T, Chang F, et al. Labeling peptide with technetium-99m using a bifunctional chelator of a N-hydroxysuc-cinimide ester of mercaptoacetyltrigycine[J]. J Nucl Med, 1998,39(1):56-64.
[5] Gano L, Patry'cio L, Marques E, et al. Human polyclonal immunoglobulin labelled with technetium-99m via NHS-MAG3:A comparisonof radiochemical behavior and biological efficacy with other labelling methods[J]. Nucl Med Bio1,1998, 25(4):395-403.
[6] Lei K, Rusckowski M, Chang F, et al. Technetium-99m antibodies labeled with MAG3 and SHNH:an in vitro and animal in vivo comparison[J]. Nucl Med Biol, 1996, 23(7):917-922.
[7] Wang Y, Chang F, Zhang Y, et al. Pretargeting with amplification using polymeric peptide nucleic acid[J]. Bioconjug Chem, 2001, 12(5):807-816.
[8] Liu G, Zhang S, He J, et al. Improving the labeling of S-acetyl NHSMAG (3)-conjugated morpholino oligomem[J]. Bioconjug Chem,2002, 13(4):893-897.
[9] Abrams MJ, Juweid M, Abrams M J, et al. Technetium-99m-human polyclonal IgG radiolabeled via the hydrazino nicotinamide derivative for imaging focal sites of infection in rats[J]. J Nucl Med, 1990, 31(12):2022-2028.
[10] Edwards DS, Liu S. 99mTc-labelling of hydrazinonicotinamide(HYNIC) modified highly potent small molecules:problems and solutions[J]. Transition Met Chem, 1997, 22(4):425-426.
[11] Ono M, Arano Y, Mukai T, et al. Control of radioactivity pharmacokinetics of 99mTc-HYNIC-Labeled polypeptides derivatized with ternary ligand complexes[J]. Bioconjugate Chem, 2002, 13(3):491-501.
[12] Verbeke K, Kieffer D, Vanderheyden JL, et al. Optimization of the preparation of 99mTc-labeled Hynic-derivatized Annexin V for human use[J]. Nucl Med Biol, 2003, 30(7):771-778.
[13] Rennen HJJM, van Eerd J E, Oyen W J G, et al. Effects of coligand variation on the in vivo characteristics of Tc-99m-labeled interleukin-8 in detection of infection[J]. Bioconjugate Chem, 2002,13(2):370-377.
[14] Su ZF, He J, Rusckowski M, et al. In vitro cell studies of technetium-99m labeled RGD-HYNIC peptide, a comparison of tricine and EDDA as co-ligands[J]. Nucl Med Biol, 2003, 30(2):141-149.
[15] Zhang YM, Liu CB, Liu N, et al. Electrostatic binding with tat and other cationic peptides increases cell accumulation of 99mTc-antisense DNAs without entrapment[J]. Mol Imaging Biol, 2003, 5(4):240-247.
[16] Welling MM, Visentinb R Feitsmaa HIJ, et al. Infection detection in mice using 99mTc-labeled HYNIC and N2S2 chelate conjugated to the antimicrobial pepfide UBI 29-41[J]. Nucl Med Biol,2004, 31(4):503-509.
[17] Rennen HJJM, Boerman OC, Koenders E B, et al. Labeling proteins with Tc-99m via Hydrazinonicotinamide (HYNIC):optimization of the conjugation reaction[J]. Nucl Med Biol, 2000, 27(6):599-604.
[18] He J, Liu C, Vanderheyden JL, et al. RadiolaboUing morpholinos with 188Re tricarbonyl provides improved in vitro and in vivo stability to re-oxldation[J]. Nucl Med Commun,2004, 25(7):731-736.
[19] Liu S, Edwards DS, Ziegler MC, et al. 99mTc-labeling of a hydrazinonicotinamide-eonjugated vitronectin receptor antagonist usefulfor imaging tumors[J]. Bioconjugate Chem, 2001, 12(4):624-629.
[20] Rennen HJJM, Makarewicz J, Oyen WJG, et al. The effect of molecular weight on nonspecific accumulation of 99mTc-labeled proteins in inflammatory loci[J]. Nucl Med Biol, 2001, 28(4):401-408.